{
    "clinical_study": {
        "@rank": "156509", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "44 mcg", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208"
            }, 
            {
                "arm_group_label": "88 mcg", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208"
            }, 
            {
                "arm_group_label": "175 mcg", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208"
            }, 
            {
                "arm_group_label": "350 mcg", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of four doses of TD-4208 and a placebo\n      product when administered once daily for 28 days using a jet nebulizer to patients with\n      moderate to severe chronic obstructive pulmonary disease."
        }, 
        "brief_title": "A 28-Day Parallel Group Study of TD-4208 in COPD", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a male or female subject 40 years of age or older\n\n          -  Subject must have a negative pregnancy test, and must be prepared to use effective\n             contraception if of child-bearing potential\n\n          -  Subject is capable of performing reproducible spirometry maneuvers\n\n          -  Subject has post-bronchodilator FEV1/FVC ratio <0.7\n\n          -  Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD\n             Guidelines)\n\n          -  Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80%\n             of predicted normal\n\n          -  Subject has a current or past smoking history of at least 10 pack-years.\n\n        Exclusion Criteria:\n\n          -  Subject has a significant respiratory disease or disorder other than COPD that would\n             affect the interpretation of data from this study\n\n          -  Subject has a history of reactions or hypersensitivity to inhaled or nebulized\n             anticholinergic or beta-agonist agents\n\n          -  Subject suffers from any medical condition that would preclude the use of inhaled\n             anticholinergic agents\n\n          -  Subject has been hospitalized for COPD or pneumonia within 12 weeks\n\n          -  Subject requires long-term oxygen therapy (>15 hours a day)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "375", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040792", 
            "org_study_id": "0117"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "44 mcg", 
                    "88 mcg", 
                    "175 mcg", 
                    "350 mcg"
                ], 
                "intervention_name": "TD-4208", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "COPD", 
            "Chronic Obstructive Pulmonary Disease"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "last_name": "Nicole Rivera", 
                "phone": "864-255-3540"
            }, 
            "facility": {
                "address": {
                    "city": "Greenville", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29615"
                }, 
                "name": "Upstate Pharmaceutical Research"
            }, 
            "investigator": {
                "last_name": "Krishna Pudi, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "Anicholls@theravance.com", 
            "last_name": "Andrew Nicholls, MD", 
            "phone": "650-808-6400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Trough FEV1", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Holter monitoring", 
                "safety_issue": "Yes", 
                "time_frame": "Screening and Day 14 or 15"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Serial FEV1 on Day 28 and Day 1", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Daily peak expiratory flow rates", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Tlast", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}